Here is a breakdown of the 10 priciest 340B medications:
- Keytruda (oncology): $6.91 billion in sales
- Biktarvy (HIV): $3.58 billion
- Opdivo (oncology): $1.95 billion
- Darzalex Faspro (oncology): $1.89 billion
- Ocrevus (oncology): $1.85 billion
- Trikafta (cystic fibrosis): $1.82 billion
- Humira (CF) Pen (immunology): $998.8 million
- Descovy (HIV): $969.5 million
- Entyvio (immunology): $949.7 million
- Durvalumab (oncology): $889.6 million
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
